DiaMedica Therapeutics DMAC 深 沪
等待开盘 07-22 09:30:00 美东时间
4.54
+0.360
+8.61%
华盛通- 最 高5.04
- 今 开4.20
- 成交量 83.12万股
- 最 低 4.1518
- 昨 收 4.18
- 总市值 1.95亿
- 52周最高 6.8184
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.19
- 委 比 9.69%
- 总股本 4288.35万
- 历史最高 10.88
- 量 比 1.65
- 振 幅 21.25%
- 历史最低 1.12
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DiaMedica Announces $30.1M Private Placement for DM199
Diamedica Therapeutics ( ($DMAC) ) has shared an announcement. On July 21, 2025...
07-21 20:56
DiaMedica Therapeutics raises $30 million in private placement
DiaMedica Therapeutics (NASDAQ:DMAC) announced on Monday definitive agreements for a $30.1 million private placement of common shares led by current investors. Pursuant to the terms of the securities ...
07-21 20:27
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
07-18 23:57
DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia
Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for
07-17 20:20
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $10 price target.
05-29 19:34
DiaMedica Therapeutics Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia On Wednesday, May 28, 2025, At 8:00 AM ET
Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM CentralDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing a novel
05-19 21:06
DiaMedica Therapeutics GAAP EPS of -$0.18 in-line
DiaMedica Therapeutics press release (NASDAQ:DMAC): Q1 GAAP EPS of -$0.18 in-line. Cash Position and Runway – Cash, cash equivalents and short-term investments were $37.3 million as of March 31, 2025,...
05-14 15:25
DiaMedica Therapeutics Q1 EPS $(0.18), Inline
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.14) per share from the same period last
05-14 04:30
